Novo Nordisk to buy Cardior Pharma for up to $1 billion

Novo Nordisk A/S bought Cardior Pharmaceuticals for $1 billion to enhance cardiovascular treatments. Cardior’s microRNA-targeting therapies aim to improve heart function, aligning with Novo’s focus on diabetes and obesity history.